Contro☆Watch⊞Compare

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

No named principal in this company's public records yet — see all operators below.

Contro is one of 2138 Healthtech companies tracked from Africa, on record since 2021. By capital raised it ranks in the long tail (ahead of 22% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

SA e-health platform Contro closes oversubscribed $585k pre-seed funding round 0 By Tom Jackson on November 14, 2022 News , Southern Africa South Africa’s Contro, a telehealth startup that focuses on sexual health and confidence treatment services, has announced the close of an oversubscribed pre-seed funding round, raising a total of ZAR10.1 million (US$585,000). Launched in May 2021, Contro offers subscription services for birth control, erectile dysfunction treatment, and hair loss treatment, as well as one-off treatment for STIs, Thrush and UTIs.

SA e-health platform Contro closes oversubscribed $585k pre-seed funding round 0 By Tom Jackson on November 14, 2022 News , Southern Africa South Africa’s Contro, a telehealth startup that focuses on sexual health and confidence treatment services, has announced the close of an oversubscribed pre-seed funding round, raising a total of ZAR10.1 million (US$585,000). Launched in May 2021, Contro offers subscription services for birth control, erectile dysfunction treatment, and hair loss treatment, as well as one-off treatment for STIs, Thrush and UTIs.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seed — a round under $1.0M). Valuation is modeled from stage benchmarks scaled by the healthtech sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Benchmarked against 2138 companies in Healthtech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 22% of sector peers (real $). Modeled value above 25% of peers (estimate).

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #39 of 174.

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

1. Pre-Seed$585K2022-11-14
   • First recorded raise — entered as Pre-Seed.
   • 3 investors on this round.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Contro is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Public records name issuer insiders, not the funds in a round — these investor links come from corroborating sources.

See where Contro sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Contro, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.